Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis.

•Abiraterone, prednisone and androgen deprivation therapy (AA + P + ADT) is at least as effective as docetaxel (DOC)+ADT in reducing the risk of death in patients with metastatic hormone-sensitive prostate cancer (mHSPC).•AA + P + ADT is associated with a lower risk of progression compared with DOC + ADT in mHSPC.•AA + P + ADT is associated with an improved QoL compared with DOC + ADT in mHSPC.•AA + P + ADT is an appropriate option for clinicians treating men with mHSPC.